Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Tufman

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Current Opinion in Oncology|November 23, 2021
Rare driver alterations in nonsmall cell lung cancer: novel targeted drugsDiego Kauffmann-Guerrero, Amanda Tufman
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Biological markers in lung cancer: A clinician's perspectiveAmanda Tufman, Rudolph Maria Huber
Zentralblatt Fur Chirurgie|February 20, 2019
[Follow-Up and Surveillance after Lung Cancer Treatment]Amanda Tufman, Thomas Duell, Christian Schneider
Theranostics|January 8, 2014
Can microRNAs improve the management of lung cancer patients? A clinician's perspectiveAmanda Tufman, Fei Tian, Rudolf Maria Huber
Expert Review of Anticancer Therapy|November 30, 2016
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIsWolfgang Brückl, Amanda Tufman, Rudolf Maria Huber
Plos One|June 13, 2019
"Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patientsJulia Walter, Amanda Tufman, Rolf Holle, et al.
Health Policy (Amsterdam, Netherlands)|September 15, 2020
Differences in therapy and survival between lung cancer patients treated in hospitals with high and low patient case volumeJulia Walter, Amanda Tufman, Rolf Holle, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 25, 2009
Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell linesAlbrecht Bergner, Julia Kellner, Amanda Tufman, et al.
JTO Clinical and Research Reports|November 13, 2024
Simultaneous Occurrence of <i>HER2</i> Mutations in <i>EGFR</i> Mutant NSCLC: Case ReportsBlerina Resuli, Diego Kauffmann-Guerrero, Jürgen Behr, et al.
AME Case Reports|November 16, 2019
Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studiesDiego Kauffmann-Guerrero, Zulfiya Syunyaeva, Kathrin Kahnert, et al.
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Current Opinion in Oncology|November 23, 2021
Rare driver alterations in nonsmall cell lung cancer: novel targeted drugsDiego Kauffmann-Guerrero, Amanda Tufman
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Biological markers in lung cancer: A clinician's perspectiveAmanda Tufman, Rudolph Maria Huber
Zentralblatt Fur Chirurgie|February 20, 2019
[Follow-Up and Surveillance after Lung Cancer Treatment]Amanda Tufman, Thomas Duell, Christian Schneider
Theranostics|January 8, 2014
Can microRNAs improve the management of lung cancer patients? A clinician's perspectiveAmanda Tufman, Fei Tian, Rudolf Maria Huber
Expert Review of Anticancer Therapy|November 30, 2016
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIsWolfgang Brückl, Amanda Tufman, Rudolf Maria Huber
Plos One|June 13, 2019
"Age matters"-German claims data indicate disparities in lung cancer care between elderly and young patientsJulia Walter, Amanda Tufman, Rolf Holle, et al.
Health Policy (Amsterdam, Netherlands)|September 15, 2020
Differences in therapy and survival between lung cancer patients treated in hospitals with high and low patient case volumeJulia Walter, Amanda Tufman, Rolf Holle, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 25, 2009
Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell linesAlbrecht Bergner, Julia Kellner, Amanda Tufman, et al.
JTO Clinical and Research Reports|November 13, 2024
Simultaneous Occurrence of <i>HER2</i> Mutations in <i>EGFR</i> Mutant NSCLC: Case ReportsBlerina Resuli, Diego Kauffmann-Guerrero, Jürgen Behr, et al.
AME Case Reports|November 16, 2019
Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studiesDiego Kauffmann-Guerrero, Zulfiya Syunyaeva, Kathrin Kahnert, et al.
Pageof 15